



## Complete Summary

---

### TITLE

Management of type 2 diabetes mellitus: percentage of patients with diabetes with eye exam documented within last 12 months.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Management of type 2 diabetes mellitus. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Nov. 80 p. [138 references]

## Brief Abstract

### DESCRIPTION

This measure assesses the percentage of patients with diabetes with eye exam documented within the last 12 months.

### RATIONALE

The priority aim addressed by this measure is to increase the percentage of patients with diabetes age 18 to 75 for whom the recommended screening frequency of dilated eye exam within the last 12 months is met.

### PRIMARY CLINICAL COMPONENT

Diabetes mellitus; eye exam

### DENOMINATOR DESCRIPTION

Number of adult patients with diabetes mellitus who had an encounter in the last month. Two options for defining the denominator are listed in the related "Denominator Inclusions/Exclusions" field of the Complete Summary.

### NUMERATOR DESCRIPTION

Patients with diabetes mellitus from the denominator who have an eye exam documented in the most recent 12 months. The nature of the exam is not specified and may be completed by any ophthalmologist or optometrist.

## Evidence Supporting the Measure

### PRIMARY MEASURE DOMAIN

Process

## SECONDARY MEASURE DOMAIN

Not applicable

## EVIDENCE SUPPORTING THE MEASURE

A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

## NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Management of type 2 diabetes mellitus.](#)

## Evidence Supporting Need for the Measure

### NEED FOR THE MEASURE

Unspecified

## State of Use of the Measure

### STATE OF USE

Current routine use

### CURRENT USE

Internal quality improvement

## Application of Measure in its Current Use

### CARE SETTING

Physician Group Practices/Clinics

### PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

### LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

### TARGET POPULATION AGE

Age 18 to 75 years

## TARGET POPULATION GENDER

Either male or female

## STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

### Characteristics of the Primary Clinical Component

## INCIDENCE/PREVALENCE

Prevalence of retinopathy is related to the duration of diabetes mellitus. After 20 years of diabetes mellitus more than 60% of patients with type 2 diabetes mellitus have some degree of retinopathy. Diabetic retinopathy is estimated to be the most frequent cause of new cases of blindness among adults ages 20 to 74 years.

Up to 21% of patients with type 2 diabetes mellitus are found to have retinopathy at the time of diagnosis of diabetes mellitus. Generally retinopathy progresses from mild background abnormalities to preproliferative retinopathy to proliferative retinopathy.

## EVIDENCE FOR INCIDENCE/PREVALENCE

Institute for Clinical Systems Improvement (ICSI). Management of type 2 diabetes mellitus. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Nov. 80 p. [138 references]

## ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

## BURDEN OF ILLNESS

Unspecified

## UTILIZATION

Unspecified

## COSTS

Unspecified

### Institute of Medicine National Healthcare Quality Report Categories

## IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness

#### Data Collection for the Measure

#### CASE FINDING

Users of care only

#### DESCRIPTION OF CASE FINDING

Number of adult patients with diabetes mellitus who had an encounter in the last month. Two options for defining the denominator are listed in the "Denominator Inclusions/Exclusions" field of the Complete Summary.

Measure may be collected electronically. If clinics do not have electronic databases or do not have registries, they may manually identify 20 patients with diabetes and collect data from medical records.

Data may be collected monthly.

#### DENOMINATOR SAMPLING FRAME

Patients associated with provider

#### DENOMINATOR (INDEX) EVENT

Clinical Condition  
Encounter

#### DENOMINATOR INCLUSIONS/EXCLUSIONS

##### Inclusions

Number of adult patients with diabetes mellitus who had an encounter in the last month. Two options for defining the denominator are listed below.

##### Definition 1

Patients 18 years or older with a primary, secondary, or tertiary diagnosis of diabetes (International Classification of Diseases, Ninth Revision [ICD-9] code 250.xx). Established patients with diabetes should be included. This requires both a visit in the target month AND a diabetic visit in a window of 12 to 24 months before the target month. Both types 1 and 2 are included\*.

##### Definition 2

Patients ages 18 to 75 continuously enrolled for the last 12 months AND

- a. two or more ambulatory visits or one acute inpatient or emergency room visit with a primary or secondary diagnosis of diabetes\* in the last 12 months: 250.xx, 362.0x (diabetic retinopathy), 366.41 (diabetic cataract), 357.2x (polyneuropathy in diabetes), or 648.0 (pregnancy excludes gestational diabetes), OR
- b. one or more prescriptions for insulin in the last 12 months (coding is available on disk from either Institute for Clinical Systems Improvement [ICSI] or from the National Committee for Quality Assurance website [NCQA.org]): regular insulin, NPH, Lente, Lispro, Humulin, 70/30, 75/25, 50/50, Novolin, Ultralente, Glargine, Aspart, Multiple Daily Injections or Continuous Subcutaneous Infusion of Insulin, Insulin Pump, Insulin Pen, Semilente, Novolin, Penfill, Ultralente, Velosulin, Humalog, OR
- c. one or more prescriptions for oral agents in the last 12 months (coding is available on disk from either ICSI or from the NCQA.org website): Acarbose, Miglitol/Glycet, Amaryl, Diabeta, Diabinese, Glimepiride, Glipizide, Glipizide XL, Glucophage, Glucotrol, Glucotrol XL, Glyburide, Glynase, Metformin, Micronase, Prandin, Starlix, Glucovance, Repaglinide, Precose, Tolazamide, Tolamide, Tolbutamide, Tolinase, Rosiglitazone, Pioglitazone.

\*Note: Both types 1 and 2 are included in both measures listed here, while the guideline (Refer to the National Guideline Clearinghouse [NGC] summary of the Institute for Clinical Systems Improvement [ICSI] guideline [Management of Type 2 Diabetes Mellitus](#)) is focused on type 2 diabetes. The inclusion of type 1 diabetes in the measures is for administrative ease, as many medical groups will not be able to determine this relatively small percentage of patients with type 1 diabetes from standard coding.

Exclusions  
Unspecified

#### NUMERATOR INCLUSIONS/EXCLUSIONS

##### Inclusions

Patients with diabetes mellitus from the denominator who have an eye exam documented in the most recent 12 months. The nature of the exam is not specified and may be completed by any ophthalmologist or optometrist.

Exclusions  
Unspecified

#### DENOMINATOR TIME WINDOW

Time window precedes index event

#### NUMERATOR TIME WINDOW

Fixed time period

#### DATA SOURCE

Administrative data  
Medical record

#### LEVEL OF DETERMINATION OF QUALITY

Individual Case

#### PRE-EXISTING INSTRUMENT USED

Unspecified

#### Computation of the Measure

#### SCORING

Rate

#### INTERPRETATION OF SCORE

Better quality is associated with a higher score

#### ALLOWANCE FOR PATIENT FACTORS

Unspecified

#### STANDARD OF COMPARISON

Internal time comparison

#### Evaluation of Measure Properties

#### EXTENT OF MEASURE TESTING

Unspecified

#### Identifying Information

#### ORIGINAL TITLE

Percentage of patients with diabetes with eye exam documented within last 12 months.

#### MEASURE COLLECTION

[Management of Type 2 Diabetes Mellitus Measures](#)

#### DEVELOPER

Institute for Clinical Systems Improvement

#### ADAPTATION

Measure was not adapted from another source.

## RELEASE DATE

2003 Nov

## MEASURE STATUS

This is the current release of the measure.

## SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Management of type 2 diabetes mellitus. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 Nov. 80 p. [138 references]

## MEASURE AVAILABILITY

The individual measure, "Percentage of patients with diabetes with eye exam documented within last 12 months," is published in "Health Care Guideline: Management of Type 2 Diabetes Mellitus." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## NQMC STATUS

This NQMC summary was completed by ECRI on July 6, 2004.

## COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2004 National Quality Measures Clearinghouse

Date Modified: 11/1/2004

The logo for FIRSTGOV, with "FIRST" in blue and "GOV" in red, and a small red star above the "I".

